Web14-Day RSI. 21.44. According to our current DCTH stock forecast, the value of Delcath Systems, Inc. shares will rise by 1.38%and reach $ 4.35 per share by August 29, … WebMar 11, 2024 · Is DCTH a good long term stock? When should I take profit in Delcath Systems stock? Buy or sell stock? Will DCTH stock price go up? What are analysts’ …
Delcath Systems, Inc. (DCTH) Stock Forecast & Price …
Web11/16/2024: Gil Aharon: Director: Buy: 2,000: $12.00 : 11/13/2024: Steven A. J. Salamon: Director: Buy: 2,000: $11.51 : See Full Table. ... DCTH) 25.66% of Delcath Systems stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock. Institutional Buying and Selling by Quarter. WebApr 8, 2024 · 3 equities research analysts have issued 12 month price objectives for Delcath Systems' shares. Their DCTH share price forecasts range from $14.00 to $19.00. On average, they expect the company's share price to reach $16.67 in the next twelve … According to the issued ratings of 2 analysts in the last year, the consensus rating for … Stock Ideas and Recommendations. Get daily stock ideas from top-performing … According to the Securities & Exchange Commission (SEC) insider trading … Of the 13 institutional investors that purchased Delcath Systems stock in the … Delcath Systems last issued its quarterly earnings results on March 27th, 2024. … Gerard J. Michel Acquires 19,646 Shares of Delcath Systems, Inc. (NASDAQ:DCTH) … Get daily stock ideas from top-performing Wall Street analysts. Get short term … View the latest news, buy/sell ratings, SEC filings and insider transactions for your … eric pashe
DCTH Stock Price Targets and Analyst Ratings)
WebMar 11, 2024 · Delcath Systems, Inc. (DCTH) share price prediction for 2024, 2024, 2025, 2026 and 2027. DCTH one year forecast. Delcath Systems stock monthly and weekly forecasts. WebFind the latest Delcath Systems, Inc. (DCTH) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. WebDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling ... eric paschall basketball